A precision medicine approach to personalized prescribing using genetic and nongenetic factors for clinical decision-making

被引:7
作者
Jamrat, Samart [1 ,2 ]
Sukasem, Chonlaphat [3 ,4 ,5 ]
Sratthaphut, Lawan [2 ,6 ]
Hongkaew, Yaowaluck [5 ,7 ]
Samanchuen, Taweesak [1 ]
机构
[1] Mahidol Univ, Fac Engn, Technol Informat Syst Management Div, Nakhon Pathom 73170, Thailand
[2] Silpakorn Univ, Fac Pharm, Artificial Intelligence & Metabol Res Grp, Nakhon Pathom 73000, Thailand
[3] Mahidol Univ, Fac Med, Dept Pathol, Div Pharmacogen & Personalized Med,Ramathibodi Hos, Bangkok 10400, Thailand
[4] Ramathibodi Hosp, Somdech Phra Debaratana Med Ctr, Lab Pharmacogen, Bangkok 10400, Thailand
[5] Bumrungrad Int Hosp, Bumrungrad Genom Med Inst, Bangkok 10110, Thailand
[6] Silpakorn Univ, Fac Pharm, Dept Biomed & Hlth Informat, Nakhon Pathom 73000, Thailand
[7] Bumrungrad Int Hosp, Advance Res & Dev Lab, Bangkok 10110, Thailand
关键词
Precision medicine; Pharmacogenomics; Knowledge representation; Decision making; Personalized prescribing; Polypharmacy; PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; DRUG; POLYPHARMACY; PERFORMANCE; VALIDATION;
D O I
10.1016/j.compbiomed.2023.107329
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Screening potential drug-drug interactions, drug-gene interactions, contraindications, and other factors is crucial in clinical practice. However, implementing these screening concepts in real-world settings poses challenges. This work proposes an approach towards precision medicine that combines genetic and nongenetic factors to facilitate clinical decision-making. The approach focuses on raising the performance of four potential interaction screenings in the prescribing process, including drug-drug interactions, drug-gene interactions, drug-herb interactions, drug-social lifestyle interactions, and two potential considerations for patients with liver or renal impairment. The work describes the design of a curated knowledge-based model called the knowledge model for potential interaction and consideration screening, the screening logic for both the detection module and inference module, and the personalized prescribing report. Three case studies have demonstrated the proof-of-concept and effectiveness of this approach. The proposed approach aims to reduce decision-making processes for healthcare professionals, reduce medication-related harm, and enhance treatment effectiveness. Additionally, the recommendation with a semantic network is suggested to assist in risk-benefit analysis when health professionals plan therapeutic interventions with new medicines that have insufficient evidence to establish explicit recommendations. This approach offers a promising solution to implementing precision medicine in clinical practice.
引用
收藏
页数:20
相关论文
共 80 条
[1]  
Alfirevic A., 2016, Medical and Health Genomics, P121, DOI DOI 10.1016/B978-0-12-420196-5.00010-1
[2]  
[Anonymous], 1992, Wolters kluwer health
[3]  
[Anonymous], 2022, Personalised Prescribing: Using Pharmacogenomics to Improve Patient Outcomes
[4]  
[Anonymous], 2015, WorldReport on Ageing andHealth, P246
[5]  
[Anonymous], 2021, Chronic kidney disease: assessment and management
[6]   The Precision Medicine Initiative A New National Effort [J].
Ashley, Euan A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (21) :2119-2120
[7]   Knowledge graph prediction of unknown adverse drug reactions and validation in electronic health records [J].
Bean, Daniel M. ;
Wu, Honghan ;
Dzahini, Olubanke ;
Broadbent, Matthew ;
Stewart, Robert ;
Dobson, Richard J. B. .
SCIENTIFIC REPORTS, 2017, 7
[8]   Sequence2Script: A Web-Based Tool for Translation of Pharmacogenetic Data Into Evidence-Based Prescribing Recommendations [J].
Bousman, Chad A. ;
Wu, Patrick ;
Aitchison, Katherine J. ;
Cheng, Tony .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[9]   Drug-Drug-Gene Interactions: A Call for Clinical Consideration [J].
Bruckmueller, Henrike ;
Cascorbi, Ingolf .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) :549-551
[10]  
Chatfield AJ., 2015, J Med Libr Assoc, V103, P112, DOI [10.3163/1536-5050.103.2.016, DOI 10.3163/1536-5050.103.2.016]